ImmunityBio (IBRX) Income from Continuing Operations (2014 - 2026)
ImmunityBio (IBRX) reported Income from Continuing Operations of 632797000.0 for Q1 2026, down 387.89% year-over-year from 219802973.51 in Q1 2025, and down 921.33% quarter-over-quarter from 61958000.0 in Q4 2025.
ImmunityBio (IBRX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 13 years of Income from Continuing Operations data on file, last reported at 632797000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 632797000.0, down 387.89% year-over-year; the trailing twelve-month figure through Mar 2026 was 854634000.0 (down 108.85% YoY), and the FY2025 annual result was 351472000.0, up 15.03% from the prior year.
- Income from Continuing Operations retreated to 632797000.0 in Q1 2026 per IBRX's latest filing, from 61958000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 59179000.0 in Q4 2024 and troughed at 632797000.0 in Q1 2026.
- A 5-year average of 141126529.41 and a median of 108326000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2026: Income from Continuing Operations soared 74.65% in 2024, then plunged 387.89% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 108326000.0 in 2022, then slumped by 115.47% to 233414000.0 in 2023, then soared by 74.65% to 59179000.0 in 2024, then fell by 4.7% to 61958000.0 in 2025, then sank by 921.33% to 632797000.0 in 2026.
- Business Quant data shows IBRX's Income from Continuing Operations at 632797000.0 in Q1 2026, 61958000.0 in Q4 2025, and 67274000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn | -632.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -632.80 Mn |
| Dec 31, 2025 | -61.96 Mn |
| Sep 30, 2025 | -67.27 Mn |
| Jun 30, 2025 | -92.61 Mn |
| Mar 31, 2025 | -129.70 Mn |
| Dec 31, 2024 | -59.18 Mn |
| Sep 30, 2024 | -85.75 Mn |
| Jun 30, 2024 | -134.58 Mn |
| Mar 31, 2024 | -134.13 Mn |
| Dec 31, 2023 | -233.41 Mn |
| Sep 30, 2023 | -95.64 Mn |
| Jun 30, 2023 | -138.21 Mn |
| Mar 31, 2023 | -116.58 Mn |
| Dec 31, 2022 | -108.33 Mn |
| Sep 30, 2022 | -111.16 Mn |
| Jun 30, 2022 | -94.84 Mn |
| Mar 31, 2022 | -103.00 Mn |
| Dec 31, 2021 | -91.55 Mn |
| Sep 30, 2021 | -88.43 Mn |
| Jun 30, 2021 | -89.39 Mn |